Fresenius, through its operating company Fresenius Kabi, is broadening its growing biopharma portfolio through a new licensing agreement with South Korea’s SamChunDang Pharm. Under the agreement, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback